The epidermal growth factor receptor ( EGFR ) gene is amplified or mutated in 30-50% of human glioblastoma multiforme. These mutations are usually associated with deletions of the INK4&alpha;-ARF locus, which encodes 2 gene products (p16 INK4a and p19 ARF ) involved in cell cycle arrest and apoptosis. We have investigated the role of EGFR mutation in gliomagenesis using avian retroviral vectors to transfer a mutant EGFR gene to glial precursors and astrocytes in transgenic mice. These mice express tv-a, a gene encoding the retrovirus receptor TVA, which is under the control of brain cell type-specific promoters. We demonstrate that expression of a constitutively active, mutant form of EGFR in cells in the glial lineage can induce lesions with many similarities to human gliomas, including increased cell density, vascular proliferation, and immunohistochemical staining for glial fibrillary acidic protein (GFAP) and nestin. We also demonstrate that primary astrocytes cultured from transgenic mice expressing tv-a from the GFAP promoter are efficiently infected in culture, and such genetically modified cell cultures can be tumorigenic in nude mice. The combinations of genetic lesions (eg, mutated EGFR, INK4a-/-) leading to tumor formation in these 2 mouse systems are similar to those found in human gliomas. These genetically defined animal models for gliomas will allow for the testing of therapies that are targeted specifically at the gene products involved in the pathogenesis of gliomas.
INTRODUCTION
Gliomas are the most common forms of primary brain tumors, and they are classified into 4 clinical grades (12, 13) . The most aggressive tumors, grade 4 tumors, also known as glioblastoma multiforme (GBM), either appear to arise de novo as GBMs or they present initially as lower grade tumors that progress to higher grades over time (27) . Certain mutations and other histologic and genetic characteristics are highly correlated with one or the other of these 2 pathogenic pathways. Gliomas that are first detected as grade 4 tumors usually lack an intact INK4a-ARF tumor suppressor locus (7, 11 ) . Cells within these tumors are thus unable to make the 2 INK4a-ARFgene products, p 16INK4a and p 19ARF that arrest the cell cycle by different pathways: in G 1 for p 16INK4a and in both G and G2 for p 19ARF (20, 24) . In addition, INK4a-ARFdeficient tumors frequently occur in older patients, contain mutations or amplification of the epidermal growth factor receptor (EGFR) gene, tend to be more aggressive, and are generally diploid (5, 6, 17, 19, 23) . In contrast, gliomas that progress from lower to higher grade lesions are usually wild type for INK4a-ARF but have an amplified cdk4 locus or have lost the Rb gene and frequently also display either loss of p53 function or amplification of mdm2. Therefore, in both types of tumors, the same 2 cell cycle arrest pathways are disrupted by different mutations. Furthermore, the tumors that retain a wild-type INK4a-ARF gene arise at an earlier age, are less aggressive, and are usually aneuploid (15, 21, 26, 28) (Figure   1 ).
We have designed a system for glia-specific gene trans-fer in vivo that allows us to investigate the effects of both individual mutations and combinations of mutations on gliomagenesis in mice (10) . This system utilizes replication-competent ALV splice acceptor (RCAS) viral vectors, derived from the avian retrovirus ALV (avian leukosis virus) subgroup A, and a transgenic mouse line (Gtv-a) that produces the receptor for ALV-A (TVA), from the astrocyte-specific promoter for the gene encoding glial fibrillary acidic protein (GFAP) (Figure 2 ). Astrocytes from Gtv-a mice are susceptible to infection and gene transfer by RCAS vectors both in vivo and in vitro.
In vivo, glia-specific gene transfer is most efficient when chicken cells that are infected with and producing virus are injected directly into the brain of transgenic mice at birth. The cells survive for a few days and infect tv-a+ cells adjacent to the needle track. We have previously used this system to show that infection with RCAS carrying the coding sequence for basic fibroblast growth factor (bFGF) (RCAS-bFGF) causes glia to proliferate, migrate over long distances, and assimilate into the normal brain structure without tumor formation (10) . Primary brain cultures can be generated from tv-a transgenic mice. These cultured cells express tv-a from GFAP+ astrocytes in the case of Gtv-a mice. These primary cultures can be infected with conditioned media from chicken cells infected with and producing RCAS vectors. These vector stocks can be mixed prior to infecting the cultures to generate multiple simultaneous gene transfer in culture. Using in vitro gene transfer, we demonstrated that both cdk4 overexpression and loss of INK4a-ARF resulted in immortalization of astrocytes in culture but that cdk4 overexpression leads to hyperploidy, whereas INK4a-ARF deficient astrocytes remain diploid (9) . These immortalized cells can be maintained in cul- ing the INK4a-ARF gene products pl6lNK4a and pI9ARF. Subdivision of human gliomas into those with mutations in INK4a-ARF and those with wild-type INK4a-ARF loci. Mutations of other genes frequently associated with these 2 tumor populations are indicated. The gliomas with mutations in INK4a-ARF are more common and are associated with abnormalities in the EGFR gene, whereas the INK4a-ARF-wild-type gliomas disrupt the G1 arrest pathways downstream of the INK4a-ARF gene products. ture for long periods and have been extensively characterized.
We have described a second transgenic mouse line expressing tv-a from the nestin promoter (Ntv-a), which is active in cells early in the glial lineage (8) . We also reported the construction and use of an RCAS vector that transfers a potent oncogene encoding a constitutively active form of EGFR (RCAS-EGFR *) to tv-a+ cells. With these and other tools, we have compared the effects of gene transfer to Ntv-a mice (presumably to glial progenitors) and to Gtv-a mice (presumably to terminally differentiated astrocytes) and asked whether EGFR*, alone or in combination with other genetic lesions observed in human gliomas, can initiate gliomagenesis (8) .
METHODS
Constructs. The Gtv-a transgene (with a 2.2-kb fragment of the GFAP promoter driving expression of the quail tv-a cDNA and a fragment from the mouse protamine gene (MP-1 ) supplying an intron and signal for polyadenylation), RCAS-AP, RCAS-bFGF, and RCAS-cdk4 have been described (9, 10) . RCAS-puro was obtained from Steve Hughes (National Cancer Institute).
The Ntv-a transgene utilizes a modified nestin promoter, including portions of its second intron, and thymidine kinase promoter sequences that have been shown to direct FIGURE 2.-tv-a Transgenes and RCAS vectors. A) Transgenes expressing the ALV subgroup A receptor TVA. The astrocyte-specific Gtv-a transgene was described previously (10) . The Ntv-a transgene utilizes a modified nestin promoter, including a portion of its second intron, and thymidine kinase promoter sequences that have been shown to direct expression to CNS progenitor cells. Transcription start sites are indicated with arrows. B) RCAS vectors carrying an exogenous gene 3' of the env gene. RCAS-EGFR* expresses a constitutively active, mutant form of human EGFR (top), with deletions of intra-and extracellular sequences as indicated. The region coding for the transmembrane domain is denoted by TM, whereas the position of the novel junction formed by the deletion in the coding region for the extracellular domain of EGFR is indicated by 8. RCAS-AP, RCAS-bFGF, and RCAS-cdk4 carry human placental alkaline phosphatase cDNA, mouse basic FGF cDNA, and human cdk4 cDNA, respectively. Although these vectors replicate only in avian cells, the exogenous genes are expressed in both avian and mammalian cells from a spliced message, as illustrated. expression to central nervous system (CNS) progenitor cells; polyadenylation sequences are provided by SV40 DNA. This transgene was constructed by Not 1 digestion of the NES 1689/lacZ plasmid (16) to release the Lac Z gene, followed by incubation with Klenow fragment of DNA polymerase and ligation to the tv-a cDNA from pSPKE 0.8 (1) , which had been digested with EcoRV and Sma 1 to achieve blunt, compatible ends. RCAS-EGFR * was constructed by Cla I digestion of RCAS-puro to remove the puromycin resistance gene, which was replaced with a fragment from pINDS'3'EGFR*, (4; gift of David James, Mayo Clinic, Rochester, NY, and Chris Thomas, Mayo Clinic, Jacksonville, FL). This fragment contains a human EGFR cDNA that lacks the sequences corresponding to exons 2-7 (bases 275-1,075) and sequence 3' of base 3133.
Mice. Production of the Gtv-a mouse line has been described (10) . The Gtv-a mouse line was originally gen-erated from an FVB/N crossed with a C57B6 X BALB/C Fl. The Gtv-a founder was then bred to an FVB/N to generate Fl progeny, which have subsequently been interbred to maintain the transgenic line. The FVB/N Ntv-a mouse line was produced by pronuclear injection of the Ntv-a transgene, which had been released from the plasmid by digestion with HinDIII. Mice with mixed C57BL/6 and 129 genetic background and with targeted, inactivated mutations of INK4a-ARF and p53 have been described previously (25) . The genetic backgrounds of the tv-a transgenic mice used for infection were therefore mixes of FVB/N, 129, C57BL6, and BALB/C. Cell Culture. Primary brain cell cultures from newborn transgenic mice were obtained by mechanical disintegration of the whole brain, followed by digestion with 0.25% trypsin for 15 minutes at 37°C. Large debris was allowed to settle, and single cells were plated and grown in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal calf serum (Gibco BRL). DF-1 cells (an immortalized line of chicken cells) were a generous gift from Doug Foster (University of Minnesota) (22) , and they were grown in DMEM with 5% fetal calf serum, 5 % calf serum, 1 % chicken serum, and 10% tryptose phosphate broth (Gibco BRL).
Infection of Cultured Astrocytes with RCAS Vectors.
The supernatant from DF-1 cells infected with and producing RCAS vectors was filtered through a 0.45-~,m filter and plated directly onto primary brain cultures from Gtv-a mice. These primary brain cultures were infected with filtered medium from RCAS-puro-producing cells and then selected in 4 pLg/ml puromycin. Infection of tv-a-Transgenic Mice with RCAS Vectors.
DF-1 cells infected with and producing RCAS vectors were harvested by trypsin digestion and pelleted by centrifugation ; the cell pellets were resuspended in approximately 50 p,l of medium and placed on ice. Using a 10-RI gas-tight Hamilton syringe, a single intracranial injection of 1 p,l, containing 104 cells, was made in the right frontal region of newborn mice, just anterior to the striatum, with the tip of the needle just touching the skull base.
Brain Sectioning and Immuno-and Histochemical Staining. Animals were sacrificed at 4-10 weeks of age; the brains were fixed in 4% formaldehyde, 0.4% glutaraldehyde, 1 x phosphate-buffered saline (PBS) for 36 hours and then dehydrated in 20% sucrose, 2% glycerol, and 1 X PBS. Frozen sections (40 pL) were obtained using a sledge microtome (Zeiss). The sections were then stained in solution for alkaline phosphatase (AP) activity using 5-bromo-4-chloro-indolyl-phosphate and 4-nitroblue-tetrazolium chloride (Boehringer), following treatment at 65°C (pH 9.5) for 30 minutes to remove endogenous alkaline phosphatase activity. The sections were then mounted on glass slides and counterstained with hematoxylin and eosin. For immunostaining, fixed frozen sections (40 [t) were stained in solution for AP as described above. The sections were then treated with 10% hydrogen peroxidase/70% methanol for 15 minutes to inactivate endogenous peroxidases. The sections were then blocked with 1 % goat serum in Tris-buffered saline (pH 8.0) with 0.1% Tween (TBST) solution for 20 minutes. This was followed by a 1-hour incubation at room temperature, following the addition of mouse monoclonal antibodies to human GFAP (Boehringer), rat nestin (Pharmingen), bovine bFGF (Calbiochem), mouse VEGF (Upstate Biochemicals), or to the vIII mutant form of human EGFR [gift of Darell Bigner, Duke University; (29) ] or rabbit polyclonal antibodies to the human vIII mutant EGFR (gift of Albert Wong, Thomas Jefferson University). After mounting on glass slides, the sections were washed extensively with TBST, and antibody staining was then visualized with peroxidase-conjugated antimouse antibody (ABC,Vector).
Injections of RCAS-Infected Cultured Astrocytes into Nude Mice. Immortalized primary astrocyte cell cultures were maintained in culture. These cells were harvested at 90% confluence by trypsin digestion and were washed in PBS. The cells were resuspended to a concentration of 1 X 106 cells/100 ~,1 PBS. One hundred microliters of the cell suspension was injected into the flanks of nude mice with a tuberculin syringe and a 21-gauge needle.
After 4-6 weeks, the mice were sacrificed and tumors resected and fixed in neutral-buffered 10% formalin. Paraffin-embedded sections (7 Rm) were obtained and stained with hematoxylin and eosin.
RESULTS

Infection of Gtv-a or Ntv-a Mice with RCAS-EGFR* Does Not Lead to Gliomagenesis
Gtv-a and Ntv-a mice were injected intracranially at birth with 1 RI containing 104 cells of a chicken fibroblast line that was producing RCAS-EGFR * (that encodes the constitutively active EGFR) and RCAS-AP (that encodes the marker gene alkaline phosphatase). Previous experiments have shown that these producer cells die and are not detectable 1 week after injection (data not shown). The producer cells infect adjacent tv-a+ astrocytes in the host animal, which results in gene transfer and expression in these cells of the gene that is carried on the RCAS vector (in this case, the activated form of EGFR).
These mice were allowed to develop and were observed until they were 8-10 weeks of age, at which time they were sacrificed, and their brains were fixed in formalin. Frozen sections of brain were stained for AP activity. Antibodies specific for the mutant form of the EGFR were used to detect expression of the virally transduced EGFR* gene product (22) . For mice infected with both RCAS-EGFR * and RCAS-AP, regions of AP-positive cells were found to be associated with immunohistochemical staining for the mutant constitutively active form of EGFR. However, no structural abnormalities were found in the brains of the 21 Gtv-a and 24 Ntv-a mice analyzed (8) . ARF+/-mice and were somewhat more common in Ntva mice (where tv-a is driven from the nestin promoter) than in Gtv-a mice (where tv-a is driven from the GFAP promoter). Lesion formation was uncommon with simultaneous transfer of EGFR* and cdk4 gene transfer to mice within a wild-type genetic background, but it occurred frequently after transferring the combination of EGFR* and cdk4 to mice with a p53-deficient background.
Infection of
Glioma-Like Lesions Are Diffuse and Associated with
Hydrocephalus and Hemorrhage
For the purpose of this study, glioma-like lesions were defined as 1) structural abnormalities seen histologically after hematoxylin and eosin staining (distortion of normal structures by cell mass or hydrocephalus); 2) increased cell density; 3) immunopositivity for the mutant form of EGFR; and 4) immunopositivity for GFAP (identifying astrocytic character) and nestin (indicating a more primitive expression pattern). Although a number of focal lesions were identified, many of the lesions were frequently diffuse and surrounded the ventricles. The lesions were often associated with abnormal blood vessels and hemorrhage into the ventricles and parenchyma; the mice often became lethargic and developed hydrocephalus and macrocephaly, and the affected animals eventually died of dehydration (Figure 3 ). Primary Astrocytes Can Be Genetically Modified in Culture Primary brain cultures were established from Gtv-a mice with either a wild-type or INK4a-ARF-/genetic background. In order to obtain a pure INK4a-ARF-/astrocyte culture, INK4a-ARF-/-Gtv-a cultures were infected with RCAS-puro and selected in puromycin.
INK4a-ARF+/+ Gtv-a cultures were infected with RCAS-cdk4. As a control, Gtv-a cultures were infected with RCAS-AP. These cells were passed in culture, and a cumulative growth curve indicating the calculated number of living cells as a function of time was generated.
These cells were further characterized by immunostaining for GFAP and nestin. Both the INK4a-ARF-/-and cdk4-overexpressing cells lost GFAP expression and expressed nestin over time. Morphologically, the cdk4overexpressing cells resembled astrocytes, whereas the INK4a-ARF-/cells appeared smaller and more progenitor-like, with fewer projections.
The above-described cdk4-overexpressing and INK4a-ARF-deficient~ultured cells were used for flank injections in nude mice. These cells were maintained in culture for a number of months, and 106 cells/100 J.11 were then used for injection. Tumors formed in the flanks of these mice within a period of 4-6 weeks. The animals were sacrificed, and the tumors were dissected, fixed in neutral-buffered 10% formalin, and sectioned. Histologic analysis of the lesions demonstrated densely cellular tumors that invaded the skin and underlying muscle and tracked along the peripheral nerve fibers (Figure 4 ).
DISCUSSION
Activation of Signal Transduction by EGFR Causes Oncogenesis Only in Conjunction with Disruption of Gl Cell Cycle Arrest
A number of tyrosine kinase receptors, including EGFR, are known to be overactive in gliomas. These receptors activate a number of common pathways, such as those involving Ras and AKt (Figure 1 ). Our data show that elevated EGFR signaling appears to be insufficient to generate glioma-like lesions. This is consistent with other observations that Ras alone is inadequate to transform cells and that expression of mutant EGFR enhances tumoriginecity in glioma cells but not in primary astrocytes (18) .
In addition to these abnormalities in signal transduction, virtually all high-grade gliomas have disruptions of both Gl arrest pathways downstream of the INK4a-ARF gene products p 16INK4a and pl9AF-F. Our cell culture data with the INK4a-ARF-deficient and cdk4-overexpressing astrocytes indicate that the phenotypic result of disrupting the G1 arrest pathways is loss of senescence and differentiation (9) . These data suggest that the combination of INK4a-ARF loss and gene transfer of an activated EGFR is sufficient to induce formation of glioma-like lesions in our mouse model.
Direct Gene Transfer Generates Diffuse Lesions with
Some Similarities to Gliomas
The patterns of genetic changes that induce gliomalike lesions by direct gene transfer are informative and hopefully will shed light on the genetic interactions in human gliomas. The mouse glioma-like lesions have similarities to human gliomas, including increased cell density, increased vascularity, and immunohistochemical staining of GFAP and nestin. However, the actual histology of the mouse lesions generated by this method does not exactly mimic that found in the human disease in that there appears to be more hemorrhaging, less pleiomorphic nuclei and mitosis, and no evidence of palisading necrosis found in human glioblastoma. The hemorrhage leads to frequent hydrocephalus and loss and distortion of brain tissue. Immunohistochemistry shows that the lesions stain for mutant EGFR and nestin. Magnetic resonance imaging scans obtained from these mice demonstrate enhancement of these lesions with gadolinium contrast, which further emphasizes the similarity between the mouse and human lesions and shows the vascular abnormalities in the mouse model (data not shown).
Gliomagenesis Requires Multiple Mutations
Combinations of mutations appear to be essential for the induction of glioma-like lesions in mice, because in our study, single mutations were incapable of generating gliomas with any measurable frequency. We have shown previously that neither bFGF (28) nor cdk4 gene transfer alone (10) results in glioma formation in mice, and p53deficient mice have not been reported to develop gliomas (3, 18) . In this report, we show that EGFR * gene transfer alone does not induce gliomagenesis. Furthermore, INK4a-ARF-deficient mice develop normally without glioma formation (4); therefore, loss of both pl6INK4a and p19A&dquo; also appears insufficient to induce gliomagenesis. Similar to the experience of others with INK4a-ARFdeficient human gliomas (17, 19-21, 26, 27) , we find an interaction between loss of INK4a-ARF and expression of mutant EGFR during gliomagenesis. In our study, the percent of mice developing EGFR*-induced gliomas was similar in INK4a-ARF+Iand INK4a-ARF-1genetic backgrounds. We were unable to test conclusively whether tumors arising in INK4a-ARF+Imice retained a functional INK4a-ARF allele. It is possible that either haploinsufficiency of the INK4a-ARF gene allows EGFR* to induce gliomas in these mice or that the tumorigenic cells are physically or functionally nullizygous.
RCAS-Infected Astrocyte Cultures Can Be Tumorigenic in Nude Mice
A second method for modeling the genetic alterations found in gliomas involves infection of tv-a + astrocytes with RCAS vectors in culture. The oncogenic characteristics of these cultured cells can then be determined. We investigated the effects of disruption of the G 1 cell cycle arrest pathways on these cultured primary astrocytes. The advantage of the RCAS/tv-a system for studying the cell cycle arrest pathways is that cell lines often have mutations in the G1 arrest pathways as a prerequisite for the cells being an immortalized line in culture. Primary cells, on the other hand, are usually difficult to genetically modify in an effective manner because of their typical low transfection efficiency. In contrast, the RCAS/tv-a system allows efficient cell type-specific gene transfer to primary cells with intact cell cycle arrest pathways.
Using the RCAS/tv-a system, we generated astrocyte cultures that were deficient in INK4a-ARF and cultures that overexpressed cdk4. Both INK4a-ARF-deficient and cdk4-overexpressing astrocytes are immortal and can be maintained in culture for long periods. In culture, these cells have been extensively characterized with respect to expression of differentiation markers, ploidy, morphology, and growth rates (10) . We injected these cell populations into nude mice and obtained tumor formation within 4-6 weeks. Any additional mutations that may have occurred during passage of these cells in culture that allowed the cells to become tumorigenic are unknown. Although these cells were initially GFAP-expressing astrocytes at the time of infection with RCAS vectors, with time in culture the cells lost GFAP expression and gained nestin expression and acquired a more progenitor-like morphology. The tumors arising from injection of these cells into nude mice have a spindle-cell morphology, can have regions of necrosis, and are negative for GFAP and S-100 by immunohistochemical staining.
Comparison of Direct Gene Transfer and Injection of RCAS-Infected Astrocyte Cultures as Methods for Modeling Gliomagenesis
The 2 methods for genetically defined glioma formation with the RCAS/tv-a system have strengths and weaknesses. An advantage of direct gene transfer in vivo is that the initiating cells are in their normal environment, and the proliferative effects are likely a direct effect of the genes transferred. A limitation of this method is that further analysis of the brain lesions is often difficult, because the lesions in the brain are frequently diffuse.
Compared to direct gene transfer, genetic modification of cultured cells followed by injection into nude mice has a number of advantages, including the following: 1) the ability to characterize the cells prior to tumor formation, 2) tumor appearance can be correlated with the characteristics of the initiating cells, and 3) the lesions obtained from nude mouse injections are more compact and easier to analyze than are those generated by direct gene transfer into the brain. A limitation of this method is that during passage in culture, cell populations may acquire other (unknown) mutations that allow for a growth advantage.
Infection of tv-a Transgenic Mice and Astrocytes with RCAS Vectors as a Method for Modeling Human
Gliomas
Various methods exist for modeling the contribution that combinations of mutations make to oncogenesis. Cell type-specific gene transfer using RCAS vectors has a number of advantages over previously reported strategies. First, with the use of transgenic mouse lines expressing tv-a in specific cell types, combinations of genes can be tested by the use of easily constructed or previously existing viral vectors. Therefore, the cost and time required to test complex combinations of genetic lesions are significantly less than for strategies in which each genetic alteration requires a separate line of mice and in which multiple matings are necessary to observe interactions between mutations (2, 14) . As reported in this manuscript, the tv-a system can also combine gain of oncogene function (by infection with RCAS vectors carrying oncogenes) and loss of tumor suppressor gene function by breeding to mice with targeted germline deletions. Second, classic transgenic strategies express oncogenes in all cells utilizing the transgenic promoter. Cells giving rise to tumors from such a population have acquired further (usually unknown) mutations, which results in tumor formation. In contrast, RCAS vectors infect only a few hundred cells in the vicinity of the injection track (10) . Therefore, any observed phenotypes are more likely to be direct effects of the transferred genes, since a smaller number of cells would be initially at risk for secondary mutations.
Genetically Defined Mouse Models for Gliomas Have
Practical Applications
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